

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Exopharm Limited
ABN	78 163 765 991

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Clarke Barlow
Date of last notice	22 February 2023

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	N/A
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	N/A
Date of change	N/A
No. of securities held prior to change	N/A
Class	N/A
Number acquired	N/A
Number disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	N/A
No. of securities held after change	N/A
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	N/A

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	Non-Executive Director Equity Entitlement
Nature of interest	Subject to shareholder approval, allotment of 10,000,000 Unlisted Options as follows: <ul style="list-style-type: none"> • 5,000,000 Unlisted Options, exercisable at 1.5 cents, expiring 48 months from the date of allotment; • 2,500,000 Unlisted Options, exercisable at 2 cents, expiring 48 months from the date of allotment; and • 2,500,000 Unlisted Options, exercisable at 3 cents, expiring 48 months from the date of allotment.
Name of registered holder (if issued securities)	Clarke Barlow or his nominee
Date of change	22 June 2023
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
Interest acquired	10,000,000 Unlisted Options (subject to shareholder approval being obtained)
Interest disposed	Nil
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	Non-cash consideration - deemed value of the 10,000,000 Unlisted Options is \$79,903.
Interest after change	10,000,000 Unlisted Options, which consists of: <ul style="list-style-type: none"> • 5,000,000 Unlisted Options, exercisable at 1.5 cents, expiring 48 months from the date of allotment; • 2,500,000 Unlisted Options, exercisable at 2 cents, expiring 48 months from the date of allotment; and • 2,500,000 Unlisted Options, exercisable at 3 cents, expiring 48 months from the date of allotment.

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.